Honyaku Center Inc. Honyaku Center Inc. Japnese chinese Site Map
Estimate Inquiries
Toppage Service Company Profile IR Info. Press Release Recruit Info. Vontact Us

Top > Investor Relations  
Investor Relations

To our shareholders and investors,
Ikuo Higashi, President
Honyaku Center Inc.

Business results for 1Q of FY2014

We would like to express our sincere gratitude to all shareholders and investors for their continued warm support and encouragement of the Honyaku Center Group.

On August 12, the Honyaku Center Group announced its business results for the first quarter of the fiscal year through March 2015.

The Group posted net sales of 2,108 million yen for the first quarter of fiscal 2014 (up 1.2% year-on-year), with operating income at 16 million yen (down 78.2%), ordinary income at 16 million yen (down 77.6%) and net income at 1 million yen (down 96.1%). Profits decreased due to an increase in selling, general and administrative expenses, despite the strong performances of the translation business, the Group's core business, and the interpretation business managed by the ISS Group.

Business results forecast for FY2014
For the fiscal year ending March 2015, the Group projects that it will achieve record highs in net sales, operating income, ordinary income and net income. Specifically, net sales are expected to be 9,400 million yen (up 7.1% year-on-year), operating income is forecast to be 480 million yen (up 31.7%), ordinary income is projected to be 480 million yen (up 33.3%) and net income is estimated to be 270 million yen (up 50.8%). The forecast remains unchanged from the initial projections.

Establishing a new company engaged in medical writing
On August 12, the Honyaku Center Group also announced its plans to establish Panacea Inc., a subsidiary specializing in medical writing. Up until now, the Group has engaged in medical writing as part of its high-value-added services of the translation business (in the medical area). With the new subsidiary, the Group will build a structure that meets the needs of pharmaceutical companies in both quality and quantity, aiming to further raise its expertise in the medical area.

We consider that the Group's mission is to sincerely acknowledge the language issues facing customers and continue expanding the scope of our language services. For fiscal 2014, the final year of its Second Mid-term Management Plan, the entire Group will do its utmost to achieve record-high earnings results.

We sincerely hope that you have gained an understanding of the Group's businesses and corporate principles, and we humbly ask for your continued support and encouragement going forward.

August 2014

Ikuo Higashi, President

To our Shareholders
and investors
  Financial Data
IR Library
  Financial Results
Securities Reports
Business Reports
Governance Report
  Company Information
IR Calendar
Stock Procedure Guide
  Stock Quote
* Link to Hercules
  Frequently Asked
Disclosure Policy
Inquire About IR
Privacy Policy
Site Policy